These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 16368438)
1. Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy. Powell CB Gynecol Oncol; 2006 Jan; 100(1):1-2. PubMed ID: 16368438 [No Abstract] [Full Text] [Related]
2. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090 [TBL] [Abstract][Full Text] [Related]
3. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246 [TBL] [Abstract][Full Text] [Related]
4. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Finch A; Shaw P; Rosen B; Murphy J; Narod SA; Colgan TJ Gynecol Oncol; 2006 Jan; 100(1):58-64. PubMed ID: 16137750 [TBL] [Abstract][Full Text] [Related]
5. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992 [TBL] [Abstract][Full Text] [Related]
6. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157 [TBL] [Abstract][Full Text] [Related]
7. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Carcangiu ML; Radice P; Manoukian S; Spatti G; Gobbo M; Pensotti V; Crucianelli R; Pasini B Int J Gynecol Pathol; 2004 Jan; 23(1):35-40. PubMed ID: 14668548 [TBL] [Abstract][Full Text] [Related]
8. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy. Gynecol Oncol; 2005 Aug; 98(2):179-81. PubMed ID: 15979696 [No Abstract] [Full Text] [Related]
9. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148 [TBL] [Abstract][Full Text] [Related]
10. Surgical risk-reduction in carriers of BRCA mutations: where do we go from here? Kauff ND; Barakat RR Gynecol Oncol; 2004 May; 93(2):277-9. PubMed ID: 15099933 [No Abstract] [Full Text] [Related]
11. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Mahajan NN Cancer; 2007 Dec; 110(12):2819; author reply 2819-20. PubMed ID: 17969078 [No Abstract] [Full Text] [Related]
12. The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer. Manchanda R; Drapkin R; Jacobs I; Menon U Gynecol Oncol; 2012 Feb; 124(2):185-91. PubMed ID: 22019526 [No Abstract] [Full Text] [Related]
13. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174 [TBL] [Abstract][Full Text] [Related]
14. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense? Olivier RI; Lubsen-Brandsma LA; van Boven H; van Beurden M Gynecol Oncol; 2005 Feb; 96(2):439-43. PubMed ID: 15661233 [TBL] [Abstract][Full Text] [Related]
15. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Finch A; Metcalfe KA; Chiang JK; Elit L; McLaughlin J; Springate C; Demsky R; Murphy J; Rosen B; Narod SA Gynecol Oncol; 2011 Apr; 121(1):163-8. PubMed ID: 21216453 [TBL] [Abstract][Full Text] [Related]
19. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Paley PJ; Swisher EM; Garcia RL; Agoff SN; Greer BE; Peters KL; Goff BA Gynecol Oncol; 2001 Feb; 80(2):176-80. PubMed ID: 11161856 [TBL] [Abstract][Full Text] [Related]
20. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience. Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]